AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Paclitaxel; Saracatinib

Criteria

Inclusion Criteria:

• Have a diagnosis of advanced ovarian cancer

• Have evidence of recurrence or disease progression at least 6 months following treatment cessation of 1st or 2nd line platinum containing therapy

• Estimated life expectancy of more than 12 weeks

Exclusion Criteria:

• Central Nervous System (CNS) metastases

• Received more than 2 prior chemotherapy regimens for ovarian cancer treatment

• Inadequate bone marrow reserve

• Inadequate liver function, renal function or low haemoglobin

• Pregnant, breastfeeding or if of child-bearing status unwilling to use an acceptable method of contraception